New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAOD-9604 vs SS-31 (Elamipretide)

AOD-9604 vs SS-31 (Elamipretide)

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
AOD-9604
Anti-Aging & Longevity
SS-31 (Elamipretide)
Summary
AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
Half-Life
30-45 minutes injectable; longer with nasal spray formulation
~2–5 hours
Admin Route
SubQ, Intranasal, Oral
SubQ
Research
Typical Dose
300-600 mcg
5–10 mg
Frequency
Once daily
Daily to several times per week
Key Benefits
  • Selective fat loss without anabolic side effects
  • No effect on blood glucose or insulin resistance
  • Improved bioavailability over Fragment 176-191
  • GRAS (Generally Recognized As Safe) status in Australia
  • Potential cartilage repair and anti-inflammatory properties
  • Does not suppress natural GH production
  • Restores mitochondrial function and ATP production
  • Protects inner mitochondrial membrane cardiolipin
  • Reduces mitochondrial reactive oxygen species (ROS)
  • Improves exercise capacity and reduces fatigue
  • Cardioprotective — studied in heart failure trials
  • Renoprotective — reduces ischemic kidney injury
  • Anti-aging via mitochondrial preservation
  • Potential in neurodegenerative disease prevention
Side Effects
  • Localized injection site reactions
  • Headache (rare)
  • Hypoglycemia risk in combination with insulin (very rare)
  • Injection site irritation
  • Nausea (rare)
  • Generally well-tolerated in clinical trials
Stacks With